|

Did Canada Just Quietly Legalize Psychedelic Therapy? Kind of, but it’s Complicated



Did Canada just legalize Psychedelic therapy?

Psychedelic therapies, such as psilocybin therapy for depression and MDMA therapy for PTSD, could soon be legal in Canada, at least for some patients. Over the holidays, Health Canada, a regulatory body similar to the FDA made a change to something called their Special Access Program (SAP). This program, before the change, allowed doctors to request a drug to treat a patient even if the drug wasn’t approved for treatment in Canada. However, doctors were not allowed to request a “restricted” drug, a category that most psychedelics fell under.

Now, under the change, which will take effect on January 5th, doctors will be able to request restricted drugs as well, meaning that on a case by case basis, patients could be prescribed psychedelic therapies such as MDMA assisted psychotherapy to treat PTSD, and psilocybin assisted therapy to treat depression.

To be clear, a request can only be made if other treatments have already failed for the patient, and there is evidence that the experimental treatment may be effective. This latter bar probably limits the decision to include just psilocybin and MDMA as these are the only psychedelics that have passed latter-stage clinical trials.

So did Canada just legalize psychedelic therapy? Well, the answer is murky, but leaning to the no side. The number of patients that will be accepted under this rule change is likely going to be few, though we don’t yet know. If thousands or tens of thousands of people are approved through this, then Canada may have backdoored the legalization of psychedelic therapy, but I do not think that this is how the regulations are going to be interpreted. In the end, though, we are just going to have to wait and see how the rule changes are applied.

Hopefully, this decision will help thousands of people with their mental health struggles.

#Psychedelics #CanadaNews #MDMA

source

Similar Posts

  • How Do our Genes Affect an LSD TRIP?? New MindMed Study [ MMED / MNMD ]

    Does our Genetic makeup influence our LSD trip?
    Hey psychedelic Investors! MindMed ( MMED/MNMD/MMQ ) recently published a study in Nature Scientific Reports examining the different variations in our genes and how they affect one’s experience during an LSD trip.

    The results are leading us to infer that, soon, we might be able to predict the strength, duration and perhaps even the subjective experience one undergoes when taking LSD based on certain genes that we possesses.

    If we’re able to do that, how will this affect LSD’s medical uses in therapy setting?

    Can we use this knowledge to move towards personalized dosing, where each individual will receive a different dose level for the same procedure, based on what their genetic code tells the therapist?
    We will answer these questions in today’s episode .
    We will also take a deep dive into the LSD study itself and explain why the findings are important for the future of psychedelic-assisted psychotherapy.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MindMedNews #MindMedstock

  • Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT

    In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).

    Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting. 

    Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.

    Excitingly, Mindset is moving towards beginning clinical trials in 2022.

    On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs. 

    In the long term, this deal has great potential for Otsuka. 

    To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:

    Can psychedelics treat mental illnesses such as depression?

    Are next-generation psychedelics better than the originals?

    What is happening in the brain when a person takes psychedelics?

    Enjoy the episode!

    You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.

    *To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/

    #MindsetPharma #DMT #microdosing